This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| B.1.1.7 | |
|---|---|
| Name | B.1.1.7 |
B.1.1.7 B.1.1.7 was a lineage of severe acute respiratory syndrome coronavirus 2 first identified in southeastern England, associated with increased transmissibility and global concern. The lineage was characterized by a constellation of mutations and was studied by teams from institutions such as University of Oxford, Public Health England, Wellcome Sanger Institute, Imperial College London, and London School of Hygiene & Tropical Medicine. Governments and agencies including National Health Service (England), European Centre for Disease Prevention and Control, World Health Organization, Centers for Disease Control and Prevention, and national public health institutes monitored its spread and implications for containment.
The lineage was assigned within the phylogenetic nomenclature systems used by groups such as Pango, Nextstrain, and researchers at the GISAID initiative and was first reported following genomic surveillance by consortia including the COVID-19 Genomics UK Consortium and sequencing efforts at the Wellcome Sanger Institute. The label reflects hierarchical naming conventions comparable to lineage designations used by panels at the International Committee on Taxonomy of Viruses and was referenced in technical briefings from Public Health England and situation reports from the World Health Organization. Early descriptions were published by research teams affiliated with University of Cambridge, University College London, and findings were discussed in policy fora at Downing Street and briefings to legislatures such as the House of Commons of the United Kingdom.
Genomic analyses identified multiple amino acid substitutions and deletions in proteins sequenced by laboratories at institutions like Wellcome Sanger Institute, including notable changes in the spike glycoprotein characterized by groups at University of Sheffield and National Institute for Health Research. Mutations reported in peer-reviewed and preprint outputs from teams at University of Edinburgh and Harvard University altered receptor-binding properties with reference to the interaction with Angiotensin-converting enzyme 2 described in structural studies from Protein Data Bank submissions and cryo-electron microscopy groups at MRC Laboratory of Molecular Biology. Laboratory assays conducted at National Institute for Biological Standards and Control and virology units affiliated with University of Oxford and Karolinska Institutet evaluated replication kinetics, cell entry, and antigenic profiles compared with contemporaneous lineages documented by GISAID.
Epidemiological investigations by Public Health England, modeling from Imperial College London, and surveillance reports from the European Centre for Disease Prevention and Control described rapid expansion in regions including Southeast England, with exportation events to countries such as United States, Denmark, Australia, Israel, and South Africa tracked using sequence sharing through GISAID and analytic platforms like Nextstrain. Travel-related introductions prompted advisories from International Air Transport Association and policy actions at national borders influenced by ministries such as the UK Home Office and United States Department of State. Outbreaks in settings overseen by authorities like Public Health Wales and Scottish Government informed local non-pharmaceutical interventions and tracing by organizations such as Test and Trace.
Clinical cohorts analyzed by hospitals including Guy's and St Thomas' NHS Foundation Trust, Royal Free Hospital, Massachusetts General Hospital, and academic centers at Johns Hopkins University provided data on hospitalization rates, intensive care utilization, and case fatality reviewed by reviewers at National Institutes of Health and advisory groups like the Joint Committee on Vaccination and Immunisation. Meta-analyses incorporating datasets from institutions such as European Centre for Disease Prevention and Control and academic groups at Yale University assessed associations with increased severity and mortality, influencing guidance issued by the World Health Organization and national public health agencies including Centers for Disease Control and Prevention.
Neutralization studies by laboratories at Moderna, Pfizer–BioNTech, and academic virology groups including University of Melbourne and University of Washington evaluated the impact of spike mutations on antibody binding, informing vaccine effectiveness assessments by regulatory agencies such as the European Medicines Agency and Food and Drug Administration. Observational vaccine effectiveness studies led by consortia including Public Health England and cohorts at Kaiser Permanente and Israel Ministry of Health compared outcomes among recipients of vaccines developed by AstraZeneca, Pfizer–BioNTech, Moderna, and others, with findings incorporated into guidance from World Health Organization technical advisory groups and immunization programs managed by Gavi, the Vaccine Alliance.
Detection relied on genomic sequencing capacity at centers like Wellcome Sanger Institute, diagnostic PCR testing networks coordinated by NHS Test and Trace and laboratories accredited by United Kingdom Accreditation Service. Surveillance strategies integrated platforms such as GISAID and analytic pipelines from Nextstrain and PANGO lineages, and diagnostics vendors including Roche, Thermo Fisher Scientific, and Abbott Laboratories evaluated assay performance. Wastewater surveillance projects at universities including University of California, San Diego and public health laboratories informed early warning systems used by municipal authorities and national agencies like Public Health England.
Responses included non-pharmaceutical interventions implemented by governments including United Kingdom, France, Germany, and Italy, travel restrictions coordinated with entities such as European Union institutions and advisories from International Air Transport Association, scaling of testing and contact tracing efforts by organizations like NHS Test and Trace and Centers for Disease Control and Prevention, and vaccine rollout programs administered by bodies including National Health Service (England) and ministries of health. Scientific communication and policy decisions were informed by advisory groups such as Scientific Advisory Group for Emergencies and modeling consortia at Imperial College London and influenced legislative oversight in parliaments such as the House of Commons of the United Kingdom and United States Congress.
Category:Severe acute respiratory syndrome coronavirus 2 lineages